Opaleye Management Inc. has made significant moves to increase its investment in Grace Therapeutics, Inc. The firm reported a series of stock purchases that have elevated its holdings to over 2.9 million shares. This strategic decision underscores Opaleye's confidence in Grace Therapeutics and its future prospects.
Opaleye Management, based in Boston, is an investment firm that specializes in managing funds and investments. The company is known for its active role in the financial markets, particularly in the pharmaceutical sector. Grace Therapeutics, the company in which Opaleye has increased its stake, operates within the pharmaceutical preparations industry, focusing on developing innovative therapies.
The recent SEC filing, with accession number 0001493152-26-047473, outlines several transactions executed by Opaleye Management. On October 14, 2026, the firm acquired 11,233 shares at a weighted average price of $1.9349. This was followed by an additional purchase of 23,485 shares on October 15 at a price of $1.9453. Most notably, on October 16, Opaleye acquired 36,347 shares at a price of $1.8917.
Following these transactions, Opaleye now owns a total of 2,944,354 shares of Grace Therapeutics. The filing indicates that these shares are held directly by Opaleye, L.P., a fund managed by Opaleye Management Inc. This ownership structure suggests that Opaleye may have a significant influence over the company’s strategic direction.
This increase in shareholding could potentially affect various stakeholders, including existing shareholders of Grace Therapeutics and competitors in the pharmaceutical preparations industry. As Opaleye solidifies its position, other companies in the sector may need to consider how this shift impacts market dynamics and investor sentiment.
Details were not available in the SEC filing regarding any future plans or initiatives stemming from this increased stake. It remains to be seen how Opaleye Management will leverage its investment in Grace Therapeutics moving forward.